Mergers & Acquisitions
Filter News
Found 20,595 articles
-
IDEX Corporation Completes Acquisition of Muon Group
11/18/2022
IDEX Corporation (NYSE:IEX) today announced that it has completed its previously-announced acquisition of micro-precision technology manufacturing company Muon B.V. and its subsidiaries (“Muon Group”).
-
Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing
11/18/2022
Orthofix and SeaSpine announced that John Bostjancic will serve as Chief Financial Officer for the new combined company, effective upon the completion of their pending merger.
-
Mesa Labs Acquires Belyntic’s Peptide Purification Business
11/17/2022
Mesa Laboratories, Inc. announced the acquisition of substantially all of the assets and certain liabilities related to Belyntic GmbH’s peptide purification business.
-
Millstone Medical Outsourcing Completes Acquisition of MycoScience
11/17/2022
Millstone Medical Outsourcing, the industry's leading partner of choice for medical manufacturers' post-manufacturing and aftermarket services, announces its completed acquisition of MycoScience, on November 14, 2022.
-
Evolent Health Announces Acquisition of Specialty Asset NIA and Strategic Partnership With Centene
11/17/2022
Evolent Health, Inc. announced that it has entered into a definitive agreement to acquire NIA, the specialty benefit management organization owned by Centene Corporation that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine, and genetics.
-
Centene Signs Definitive Agreement to Divest Magellan Specialty Health
11/17/2022
Centene Corporation announced that it has signed a definitive agreement to sell Magellan Specialty Health to Evolent Health, Inc.
-
In the acquisition, announced Wednesday, Kriya picks up two gene therapy programs focused on epilepsy and trigeminal neuralgia. Financial terms of the deal were not disclosed.
-
Stealth BioTherapeutics Corp Announces Completion of Merger
11/16/2022
Stealth BioTherapeutics Corp announced the completion of the merger with Stealth Merger Sub Limited.
-
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
11/16/2022
Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.
-
Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio
11/16/2022
Kriya Therapeutics, Inc. today announced the acquisition of Redpin Therapeutics, Inc., a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system.
-
Health Tech Company CardieX Acquires Wearable Sensor Startup Blumio
11/15/2022
CardieX Limited, a global health technology company focused on cardiovascular disease, announced that it has acquired all the assets of Blumio, Inc., a Silicon Valley based developer of advanced algorithms and technology for cardiovascular sensors, signifying the company's continued investment in cardiovascular health monitoring technologies.
-
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.
11/15/2022
Larkspur Health Acquisition Corp. and ZyVersa Therapeutics, Inc. are pleased to announce that Larkspur's proxy/registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission on August 12, 2022, as amended, was declared effective by the SEC on November 14, 2022.
-
Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.
11/15/2022
Frazier Lifesciences Acquisition Corporation announced that its shareholders voted to approve the proposed business combination with NewAmsterdam Pharma Holding B.V., a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases.
-
Indivior PLC announced it will acquire Opiant Pharmaceuticals and its lead candidate OPNT003, an intranasal-delivered opioid overdose recovery product.
-
TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation
11/14/2022
TriSalus Life Sciences® announced it has entered into a definitive merger agreement with MedTech Acquisition Corporation, a publicly traded special purpose acquisition company.
-
Indivior To Acquire Opiant Pharmaceuticals
11/14/2022
Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash, plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch.
-
Indivior PLC to Acquire Opiant Pharmaceuticals
11/14/2022
Opiant Pharmaceuticals Inc. announced that it has entered into a definitive merger agreement to be acquired by Indivior Inc, a subsidiary of Indivior PLC.
-
Telix Acquires Optimal Tracers
11/13/2022
Telix Pharmaceuticals Limited announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials.
-
Bridgewest Group inks deal with Pfizer to acquire injectable manufacturing plant in Western Australia
11/11/2022
Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, is expanding its portfolio.
-
Skye Bioscience Closes Acquisition of Emerald Health Therapeutics
11/11/2022
Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has concluded the merger transaction with Emerald Health Therapeutics ("Emerald"). Both companies' shareholders voted in favor of the transaction and the Supreme Court of British Columbia approved the transaction.